UPDATED – NYSE American Past Champ (ATNM) Could Be Geared Up For Another Major Breakout Based On Key Bullish Technicals






0.00 | 0.00%


0.00 - 0.00



52-Week Low/High

9223372036854775808.00 - 0.00

12/9/22 *UPDATED*

Greetings Readers,

ATNM had a strong showing Thursday.

Hitting this week’s high of $11.32, ATNM got some serious backing from a huge press release.

Check it out here: Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative

Dr. Avinash Desai, Actinium’s Chief Medical Officer, shared in the article:

These results give us confidence that Actimab-A will effectively eliminate any residual leukemia cells in this post-transplant setting where the leukemia burden is expected to be much lower. In addition to improved leukemia cell killing, Actimab-A’s highly targeted nature has been shown to be well tolerated with minimal extramedullary toxicities. We look forward to the oral presentation at ASH and to advancing this collaboration and furthering Actimab-A’s utility in treating patients with AML.

Pretty big stuff. Make sure to read the entire article if you haven’t yet because there is a ton of important info in there.

On top of that, Barchart continues to report a total of 12 triggered technical indicators at the moment including the website’s “Trend Seeker” composite indicator.

Plus, don’t forget, it was only back in October when 3 different analysts raised their price targets on ATNM.

With their bullish outlook on ATNM’s future, it’s important to get this NYSE American profile back on your radar today.

If there are any updates after the opening bell, I’ll have them out to you quickly.


Virtus Junxit


Greetings Readers,

Listen. Not often are we given second chances in life.

But in the markets… Anything can happen.

Take for example what happened when I brought APCX back to your attention recently.

When I first alerted it back in October, it ran approximately 60% in a handful of days.

Then, when I delivered it back to your inboxes at the end of November, it ran approximately 52.5% in 3 short days.

To put it simply, 2nd chances in the market do exist, and after APCX made a pull back, it delivered once again.

Now, I want to bring your attention back to another profile for a second time.

When I alerted this profile the first time, it ended up going on a mind-blowing run.

Could round 2 be staring us in the face after a recent pullback?

Let me get to it. Actinium Pharmaceuticals (NYSE American: ATNM) needs your attention Thursday.

Here’s why…

The leukemia therapeutics market could reach $17.1Bn by 2024 up from $12.3Bn in 2019, at a CAGR of 6.8%.

Do you know what’s driving this market? A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

Some must also contend with relapsed, or recurrent, acute myelogenous leukemia (AML), which means leukemia came back after treatment and after reaching remission.

Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells.

The increasing number of approvals of novel and innovative drugs and immunotherapies is evidence of an increasing need for leukemia therapies.

Say hello to a wide-open opportunity for Actinium Pharmaceuticals (ATNM).

Iomab-B: Being Developed to Disrupt the Field of BMT (Bone Marrow Transplant)

First-in-Class CD45 targeted radiotherapy with a strong pedigree and robust clinical data showing consistent access to potentially curative BMT and improved outcomes

  • Developed to achieve myeloablative conditioning with the tolerability of reduced intensity conditioning
  • CD45 is uniquely expressed on blood cancer, immune and bone marrow stem cells at high levels ~200,000 copies per cell
  • CD45 is not expressed outside the hematopoietic system and has low internalization rates ~10%
  • Blood cancers are highly sensitive to radiation allowing Iomab-B to simultaneously destroy cancer cells (induction/remission) and immune cells (conditioning)

Grab more key ATNM and Iomab-B details from the updated company presentation here.


Price Targets Galore – Strong Analyst Coverage Could Provide A Glimpse Of ATNM’s Future

Check this out from MarketBeat:


If by chance you’re reading this report without having pulled up ATNM yet, let me fill you in.

Yesterday, ATNM closed the session at $10.54.

That means it has at least 3 analyst price targets over 100% higher than its current valuation.

The max $53 target from HC Wainwright provides a mind-blowing 400+% potential upside.

Now, do we expect ATNM to go surging to those heights this week? No. But it’s important to take note of the sheer amount of large price targets in comparison to ATNM’s current valuation.


Bullish Technicals – ATNM’s Key Triggered Technicals Need Immediate Focus

Over at Barchart, the website is highlighting ATNM’s bullish triggered technicals over the short, medium, and long term.

Take a look for yourself:

Short Term Indicators

  • 20 – 50 Day MACD Oscillator
  • 20 – 100 Day MACD Oscillator
  • 20 – 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 – 100 Day MACD Oscillator
  • 50 – 150 Day MACD Oscillator
  • 50 – 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 – 200 Day MACD Oscillator

On top of these, Barchart’s composite “Trend Seeker” technical indicator is also triggered at the moment.

Make sure to watch these technicals closely moving forward.


ATNM’s Low Float

Time’s running thin so let me get straight to this one. ATNM has a low float.

Yahoo Finance is reporting its float to be approximately 24.59Mn. Why is this important?

With smaller floats, the potential for volatility is greater.

When a company delivers positive news and they have a low float, the potential for significant intraday moves becomes more prevalent.

The Proof’s In The Pudding – Positive Top Line Data Provides A Spark For ATNM

At the end of October, ATNM went on a tear up to over $15. Now, what might have caused that?

Potentially these two things: a low float and huge news.

Check out what came down the pipeline:

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

–  Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001

NEW YORK, Oct. 31, 2022 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a conditioning regimen prior to a Bone Marrow Transplant (BMT) versus a control arm which allowed all current means of conventional care with the intent to transplant these patients. The SIERRA trial met its primary endpoint of durable complete remission or dCR of 6 months post initial remission after a BMT in Iomab-B arm compared to conventional care arm demonstrating statistical significance p<0.0001.

Dr. Avinash Desai, Actinium’s Chief Medical Officer, added, “We are excited that the randomized, controlled, multi-center, pivotal SIERRA trial has delivered these results for patients that need new treatment options. Our goal is to increase access to BMT and improve patient outcomes with Iomab-B, and these topline results move us in this direction given their statistical significance. We will continue to work on our Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for approval of Iomab-B. On behalf of Actinium, I’d like to thank the patients who took the leap of faith and enrolled in the SIERRA trial, their families and caregivers who supported them and the investigators who contributed their efforts and advice who made this trial possible. Without them it would not have been possible to yield these results that will enable us to continue to develop Iomab-B.

Sandesh Seth, Actinium’s Chairman and CEO, said, “This is a significant milestone in Actinium’s lifecycle and a testimony to the quality of our team who undertook a pioneering study in a patient population that is considered largely futile to treat. Despite being perennially under-staffed and under resourced, their passion and perseverance has yielded a clinically meaningful dividend. Our recently strengthened team is executing to enable our mission to disrupt the field of bone marrow conditioning with Iomab-B, first in r/r AML and then by building upon its robust prior clinical results in several hematological diseases. We look forward to sharing additional clinical data from the SIERRA trial by year end.

Read the full article here.

As you can see from what I highlighted above, the company is looking to share more info before the end of the year.

Could that news turn into another major catalyst for ATNM moving forward?

Take a moment now and get Actinium Pharmaceuticals (NYSE American: ATNM) on your screen ahead of the opening bell.


Virtus Junxit






0.00 | 0.00%


0.00 - 0.00



52-Week Low/High

9223372036854775808.00 - 0.00



Pursuant to an agreement between Virtus Junxit, LLC and a third party media buyer, Virtus Junxit has been hired for a period beginning on 12/7/2022 to publicly disseminate information about (ATNM:US) via digital communications. We have been paid twenty-five thousand dollars USD via bank wire transfer. We own zero shares of (ATNM:US).


You understand that the information distributed is not considered buy or sell advice, and independent due diligence should be conducted and/or advice from a registered investment advisor before making investment decisions.

Our Digital Assets, Virtus Junxit LLC, VJ Newsletters, VJ SMS, Virtus Junxit Equities and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities.

Our Digital Assets may also contain company profile pages, which are indicated as such. Information about a company contained on a company profile page has been furnished by the company or third-parties. The owner/operator of Our Digital Assets has not made any independent investigation of the accuracy of any such information and no warranty of the accuracy of any such information is provided by Our Digital Assets, its owners, employees and affiliates.

No investment advice is provided or should be construed to be provided herein. Our Digital Assets and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker- dealers or registered investment advisors. Our Digital Assets may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein.

Accordingly, users of Our Digital Assets are cautioned not to place undue reliance on such forward-looking statements. Our Digital Assets undertakes no obligation to update any forward-looking statements that may be contained herein. Disclaimer continued, please read further at this link.